To determine how pro-metastatic systemic inflammation is influenced by genetic aberrations in tumours, we studied 16 genetically engineered mouse models (GEMMs) for breast cancer carrying different tissue-specific mutations. These GEMMs represent most subtypes of human breast cancer, including ductal and lobular carcinoma, oestrogen receptor-positive (luminal A), HER2 + , triple-negative and basal-like breast cancer. Because we and others have demonstrated that neutrophils expand systemically and promote metastasis [5][6][7][8][9][10] 
+
, triple-negative and basal-like breast cancer. Because we and others have demonstrated that neutrophils expand systemically and promote metastasis [5] [6] [7] [8] [9] [10] , we evaluated circulating levels of neutrophils as a marker for systemic inflammation in mammary tumour-bearing mice with end-stage disease. As expected, most tumour-bearing mice displayed an increase in circulating neutrophils compared with non-tumour-bearing wild-type animals (Fig. 1a) . Like the inter-patient heterogeneity in systemic inflammation in human breast cancer 11 , we observed a striking variability in the extent of neutrophilia between the different tumour-bearing GEMMs (Fig. 1a, Extended Data Fig. 1a) . We found that the models exhibiting high neutrophil expansion displayed a subset of neutrophils expressing the stem-cell marker cKIT (Fig. 1b) , indicative of an immature neutrophil phenotype 5 . We subsequently searched for commonalities and differences among the 16 GEMMs with regards to high versus low levels of systemic neutrophils. Notably, mice bearing tumours with a p53 deletion exhibited the most pronounced levels of circulating neutrophils (Fig. 1a) . The difference in the magnitude of systemic inflammation between p53-proficient and p53-null tumours was even more apparent when focusing on cKIT + neutrophils (Fig. 1b) . In mouse models for colorectal, pancreatic, prostate and endometrial cancer, p53 mutation or loss leads to recruitment and activation of immune cells in the primary tumour microenvironment [12] [13] [14] [15] [16] . To study the association between p53 status of the tumour and systemic inflammation, we separated the 16 GEMMs based on the presence or absence of homozygously floxed Trp53 alleles and compared the levels of circulating neutrophils and the proportion of cKIT-expressing neutrophils. This analysis confirmed a statistically significant difference between mice bearing p53-proficient and p53-null tumours (Fig. 1c, d ).
We previously demonstrated that expansion of neutrophils in mammary tumour-bearing Krt14 (K14)-cre;Cdh1
F/F (KEP) mice is driven by an inflammatory pathway that involves CCL2, IL-1β, IL-17A and granulocyte colony-stimulating factor (G-CSF) 5, 17 . We found that serum levels of CCL2, IL-1β and G-CSF correlated with p53 loss in primary tumours in the 16 GEMMs ( Fig. 1e-h ). Principal component analysis of these systemic immune parameters further demonstrated that systemic inflammation correlated with the p53 status of the tumour (Fig. 1i) .
To provide evidence for a causal relationship between p53 loss in mammary tumours and neutrophilia, we derived cancer cell lines from two independent p53-proficient tumour models-Wap-cre;Cdh1 (WEP) . Using CRISPR-Cas9-mediated gene disruption, we targeted Trp53, which resulted in an inability to increase p21 levels after irradiation (Extended Data Fig. 2a, b, e (Fig. 2a) . Although the loss of p53 conferred a proliferation advantage in vitro, growth kinetics in vivo were similar between p53-proficient and p53-deficient tumours for both cell lines (Extended Data Fig. 2c-g ). Consistent with our findings in the GEMM panel, we observed increased expansion of neutrophils, including cKIT + neutrophils, in the circulation and lungs of mice bearing WEA;Trp53 −/− and WEP;Trp53 −/− tumours, when compared with mice bearing size-matched p53-proficient tumours Extended Data Fig. 2h, i) . In addition, mice with WEA;Trp53
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Because we observed cKIT + immature neutrophils in p53-null tumour-bearing mice (Figs 1d, 2d), we next investigated whether haematopoiesis was altered. In mice bearing WEA;Trp53 −/− tumours, the frequencies of Lin − Sca1 + cKIT + cells, common myeloid progenitors, CD11b
+ Ly6G low pro-myelocytes and mature neutrophils were increased in the bone marrow at the expense of megakaryocyte and erythrocyte progenitors, when compared to WEA;Trp53 +/+ tumour-bearing mice (Extended Data Fig. 3a-c) . This effect on cell proportions was not reflected in the total cell counts, possibly owing to a slight depletion of total bone marrow cell numbers in WEA;Trp53 −/− tumour-bearing mice (Extended Data Fig. 3d ).
Previously, we reported that macrophage-derived IL-1β in the tumour microenvironment triggers systemic neutrophil expansion in KEP mice 5 . Because serum levels of IL-1β correlated with p53 status (Fig. 1f) , we proposed that loss of p53 changes the secretome of cancer cells, stimulating IL-1β production from tumour-associated macrophages (TAMs) and setting off a systemic inflammatory cascade. Indeed, in vitro exposure of bone marrow-derived macrophages (BMDMs) to conditioned medium from WEA;Trp53 −/− or WEA;Trp53 +/+ cancer cells differentially affected their phenotype (Extended Data Fig. 4a ). Notably, conditioned medium from WEA;Trp53 −/− and WEP;Trp53 −/− cells strongly induced Il1b mRNA expression in cultured BMDMs compared with conditioned medium from matched Trp53 +/+ controls (Fig. 2e ). In agreement with our mouse data, human monocyte-derived macrophages (MDMs) cultured with tumour conditioned medium of TP53 −/− MCF-7 human breast cancer cells displayed increased CD206 and CD163 expression compared with human MDMs cultured with conditioned medium of p53-proficient MCF-7 cells (Extended Data Fig. 4c ). We also observed increased IL1B expression in human MDMs after exposure to TP53 −/−
MCF-7 cells compared with TP53
+/+ controls (Extended Data Fig. 4d ). These data indicate that cancer-cell-intrinsic p53 status dictates the crosstalk between cancer cells and macrophages in a paracrine fashion, resulting in an altered macrophage phenotype and IL-1β production. We also observed increased levels of IL1B mRNA expression in breast tumours of The Cancer Genome Atlas (TCGA) with mutations in TP53 compared with wild-type TP53 tumours (Fig. 2f) , suggesting similar p53-dependent activation of IL-1β signalling in human breast cancer.
To identify which factor(s) in p53-null tumours mediate TAM activation and subsequent systemic inflammation, we performed RNA sequencing on mammary tumours of 12 different GEMMs (7 p53-null models, 5 p53-proficient models; 145 tumours in total). The p53-deficient tumours differed substantially from p53-proficient tumours in terms of gene expression, regardless of any additional genetic aberrations, demonstrating a dominant effect of p53 loss on the global transcriptome (Extended Data Fig. 5a ). Interestingly, the most significantly changed pathways in p53-deficient tumours pertained to adaptive immune phenotypes (Fig. 3a) . Although neutrophil and TAM numbers were altered intratumourally, the composition of CD8 (n = 4, 3, 4, 7, 3, 4, 4, 3, 6, 7, 6, 9, 3, 5, 4, 7 and 7 mice, top to bottom). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, compared to wild-type control by two-tailed one-way analysis of variance (ANOVA) with Tukey's multiple-testing correction. c, d, Total neutrophil frequencies (c) and
−/− (n = 46) tumour-bearing mice, combined from a and b. e-h, CCL2 levels (n = 17 Trp53 +/+ , n = 22 Trp53 −/− ) (e), IL-1β levels (n = 18 Trp53 +/+ , n = 21 Trp53 −/− ) (f), IL-17A levels (n = 24 Trp53 +/+ , n = 30 Trp53 −/− ) (g) and G-CSF levels (n = 22 Trp53 +/+ , n = 33 Trp53 −/− ) (h) in serum of GEMMs at end stage based on p53 status. P values in c-h determined by two-tailed Mann-Whitney U-test. i, Principal component analysis of data depicted in a-h (13 out of 16 GEMMs). Each symbol represents one mouse. Circles contour 40% of group-specific Gaussian probability distributions of sample scores. All data are mean ± s.e.m. Fig. 5b-g ), suggesting that the distinct transcriptome profiles are not due to a p53-dependent effect on the composition of the adaptive immune landscape.
Letter reSeArCH
From the Gene Ontology analysis, we selected genes that encode secreted factors that could potentially influence TAMs. One of the upregulated pathways in p53-null tumours included WNT and β-catenin signalling (Fig. 3a) . WNT signalling is linked to the production of IL-1β in acute arthritis, as well as immune and stromal signalling in cancer [20] [21] [22] [23] . Using a WNT and β-catenin signalling gene signature, we found that p53-null GEMM tumours clustered separately from a b ). e, Quantitative PCR with reverse transcription (RT-qPCR) analysis of the expression of Il1b in BMDMs after exposure to conditioned medium from Trp53 +/+ and Trp53 −/− WEA or WEP cell lines (n = 4 or n = 3 biological replicates per group). Plots are representative of three independent experiments with two technical replicates per biological replicate. f, IL1B expression in TP53 wild-type (n = 643) or TP53 mutant (MUT, n = 351) human breast tumours of the TCGA database. Data in b-e are mean ± s.e.m. Box plots in f are as described in Fig. 3e . P values were determined by two-tailed Mann-Whitney U-test (b-d, f) or two-tailed one-way ANOVA with Tukey's multiple-testing correction (e). Letter reSeArCH p53-proficient tumours, indicating an association between loss of p53 and WNT-related gene expression (Extended Data Fig. 6a, b ). Many WNT-related genes were upregulated in p53-deficient tumours, including three WNT ligands, Wnt1, Wnt6 and Wnt7a, whereas the expression of negative regulators of WNT signalling was decreased (Fig. 3b, Extended Data Fig. 6c ). Increased protein levels of WNT1 and WNT7A were confirmed in a set of independent p53-deficient tumours (Fig. 3c, d ). We also found increased expression of non-phosphorylated β-catenin, indicative of activated WNT signalling (Fig. 3c, d ). In human breast tumours, expression of WNT1, WNT6 and WNT7A was increased after aberrant expression of TP53, compared with wild-type TP53 tumours (Fig. 3e) . We then broadened our analysis of TCGA data to other WNT-related genes and discovered a trend towards enrichment of these genes in TP53-mutated tumours (Extended Data Fig. 6d ). In addition, individual WNT-stimulating genes were upregulated, whereas WNT-inhibiting genes were downregulated in mutant versus wild-type TP53 human tumours (Extended Data Fig. 6e ), indicating that WNT signalling is activated after aberrant expression of TP53. Using WEA cell lines, we confirmed that the WNT1, WNT6 and WNT7A proteins are increased intracellularly in WEA;Trp53 −/− cells and secreted, when compared with WEA;Trp53 +/+ cells (Fig. 3f ). Collectively, these data indicate cancer-cell-autonomous secretion of WNT ligands after loss of p53.
Because deletion of p53 increases WNT ligand expression, we proposed that wild-type p53 negatively regulates these genes, either directly or indirectly. To determine whether p53 binds the regulatory regions of Wnt1, Wnt6 and/or Wnt7a, we performed chromatin immunoprecipitation followed by high-throughput sequencing (ChIPseq) in three independent WEA and WEP cell lines. p53 binding was observed at the Cdkn1a (p21) locus (Extended Data Fig. 7a ), whereas we did not find p53 binding at the Wnt1, Wnt6 or Wnt7a loci (Extended Data Fig. 7b ), suggesting that p53 regulates their expression indirectly. Because p53 has been described to control Wnt1 expression by activating microRNA-34a (miR-34a) 24 , we wondered whether this microRNA may be involved in the regulation of Wnt1, Wnt6 and Wnt7a. Indeed, we observed p53 chromatin binding at the miR-34a locus in all cell lines (Extended Data Fig. 7c ). Overexpression of miR-34a in WEA;Trp53 −/− cells resulted in a significant reduction of WNT ligand expression (Extended Data Fig. 7d ). These data suggest that wild-type p53 negatively regulates the expression of Wnt1, Wnt6 and Wnt7a via miR-34a.
We then assessed the role of cancer-cell-derived WNT ligands on IL-1β production by macrophages. We treated WEA cells with LGK974-which inhibits porcupine (encoded by Porcn), a WNTspecific acyltransferase that regulates WNT ligand secretion 25 -and added conditioned medium to macrophages. LGK974 reduced the WEA;Trp53 −/− cell-induced Il1b expression by macrophages (Fig. 4a ). We also depleted Porcn in WEA;Trp53 −/− cells using short hairpin RNAs (shRNAs), which resulted in reduced macrophage expression of Il1b, consistent with pharmacological inhibition of porcupine (Fig. 4a) . These data confirm a causal relationship between WNT ligand secretion by p53-deficient cancer cells and IL-1β expression in macrophages.
To identify the receptors involved in the crosstalk between p53-null cancer cells and macrophages, we looked for genes that encode WNT receptors in the GEMM gene expression data. We found that 
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Frizzled receptors, Fzd7 and Fzd9, were upregulated in the p53-null tumours compared with p53-proficient tumours (Extended Data Fig. 8a ). Similarly, expression of FZD7 and FZD9 was increased in mutant TP53 human breast tumours compared with wild-type TP53 tumours (Extended Data Fig. 8b ). We then used small interfering RNAs (siRNAs) to knockdown both Fzd7 and Fzd9 in BMDMs (Extended Data Fig. 8c ), which prevented induction of Il1b by WEA;Trp53 −/− cells (Extended Data Fig. 8d ), demonstrating that FZD7 and FZD9 are involved in WNT-induced activation of macrophages in vitro.
We next assessed whether the production of WNT ligands by p53-deficient cancer cells drives systemic inflammation. We treated tumour-bearing KEP mice with LGK974 for five consecutive days, and this led to a reduction in the levels of total neutrophils and cKIT + neutrophils in blood and lungs when compared with vehicle-treated KEP mice (Fig. 4b, Extended Data Fig. 9a ). In addition, IL-17A-producing γδ T cells-the key cell type responding to IL-1β that drives neutrophil accumulation and consequently metastasis 5 -were reduced in the lungs of LGK974-treated KEP mice (Extended Data Fig. 9b ), indicating that γδ T cell activation upstream of pro-metastatic neutrophil accumulation depends on WNT signalling. Similarly, long-term treatment of KEP mice with LGK974 blocked neutrophil expansion over time (Extended Data Fig. 9c ). To exclude the possibility that the observed reduction in inflammation is a result of targeting non-tumour cells by LGK974, we orthotopically transplanted WEA;Trp53
;shPorcn cell lines and matched WEA;Trp53
;shControl cells into wild-type mice. Analysis of size-matched end-stage tumours revealed an incomplete reduction of Porcn expression (Extended Data Fig. 9d ). Although we cannot formally exclude the possibility that non-cancer cells contribute to the residual Porcn expression, expression levels of Porcn in the tumours correlated with levels of circulating neutrophils, cKIT + neutrophils and Il1b expression (Extended Data Fig. 9e-g ). Moreover, knockdown of Porcn prevented splenomegaly (Extended Data Fig. 9h ). Collectively, these data confirm the causal link between WNT secretion triggered by p53-deficient mammary tumours and systemic inflammation.
Because the γδ T cell-neutrophil axis promotes metastasis 4,5 and these cells are regulated by WNT ligands, we proposed that LGK974 treatment may present a viable therapeutic strategy to inhibit metastasis of p53-null mammary tumours. To test this, we treated KEP tumour-bearing mice with LGK974 or vehicle, after which we surgically removed the primary tumour and assessed metastatic progression. Notably, although blockade of porcupine did not affect the growth of primary tumours (Extended Data Fig. 9i ), pulmonary metastases were reduced (Fig. 4c, d ). In an independent metastasis model in which we orthotopically transplanted matched Trp53 +/+ and Trp53 −/− WEP cell lines, we observed that the absence of p53 increases lung metastasis formation (Fig. 4e , left and right graphs; P = 0.0153). We then treated both WEP;Trp53 +/+ and WEP;Trp53 −/− tumour-bearing mice with LGK974, which failed to influence primary tumour growth (Extended Data Fig. 9j ). However, LGK974 treatment reduced metastasis of WEP;Trp53 −/− tumours, without affecting metastasis of WEP;Trp53 (Fig. 4e, f) . These data show that blocking WNT-induced systemic inflammation impedes metastasis formation of p53-null mammary tumours. In summary, we show that the status of p53 is an important driver of systemic pro-metastatic inflammation in breast cancer (Extended Data Fig. 9k ) and that targeting WNT signalling may represent a promising therapeutic modality for patients with p53-deficient breast tumours. Together with recent literature on the importance of canonical driver mutations in shaping the local immune composition of primary tumours 26 , our findings shed light on the poorly understood inter-patient heterogeneity in the systemic composition and function of immune cells. Mechanistic understanding of the intricate interactions between cancer-cell-intrinsic genetic events and the immune landscape provides a basis for the design of personalized immune intervention strategies for patients with cancer.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/ s41586-019-1450-6. ;SB, which were on BALB/c and a mixed genetic (C57BL/6J and FVB/N) background, respectively. Female mice were monitored twice weekly for the onset of spontaneous mammary tumour formation by palpation starting at 6-7 weeks of age. The perpendicular tumour diameters of mammary tumours were measured twice per week using a calliper, and tumour volume was calculated using volume (mm 3 ) = 0.5(length × width 2 ). Maximum permitted tumour volumes were 1,500 mm 3 . Age-matched wild-type littermates were used as controls. Average systemic total and cKIT + neutrophil levels in non-tumour-bearing FVB/N and BALB/c mice were similar (data not shown). For orthotopic transplantation experiments, 1 × 10 6 cells were injected into the right fourth mammary fat pad of wildtype FVB/N mice (Janvier Labs , and surgical removal of the primary tumours was hampered by their highly invasive growth. For intervention studies, mice were randomly distributed over the two treatment arms when tumours reached the indicated size. Tumour measurements and post-mortem analyses were performed in a blinded fashion. Mice were kept in individually ventilated cages, and food and water were provided ad libitum. The maximal permitted disease end points were not exceeded in any of the experiments. Flow cytometry. Flow cytometry analysis was performed as previously described 5 . In brief, tissues were collected in ice-cold PBS and blood was collected in tubes containing heparin. Tumours and lungs were mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory Engineering). Tumours were digested for 1 h at 37 °C in 3 mg ml −1 collagenase type A (Roche) and 25 µg ml −1 DNase (Sigma) in serum-free DMEM medium. Lungs were digested for 30 min at 37 °C in 100 µg ml Liberase TM (Roche). Enzyme reactions were stopped by addition of cold DMEM, 8% fetal calf serum (FCS) and suspensions were dispersed through a 70-µm cell strainer. Bone marrow was collected from the tibia and femurs of both hind legs and flushed using RPMI, 8% FCS through a 70-µm cell strainer. Single-cell suspensions were treated with NH 4 Cl erythrocyte lysis buffer. Before staining, cell suspensions were subjected to Fc receptor blocking (rat anti-mouse CD16/32, BD Biosciences) for 15 min at 4 °C, except for bone marrow (to allow assessment of CD16/32 expression). Cells were stained with conjugated antibodies for 30 min at 4 °C in the dark in 0.5% BSA in PBS. 7AAD (1:20; eBioscience/ThermoFisher) or Fixable Viability Dye eFluor 780 (1:1,000; eBioscience/ThermoFisher) was added to exclude dead cells. For intracellular cytokine staining, single-cell suspensions were stimulated in IMDM containing 8% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin, 0.5% β-mercaptoethanol, 50 ng ml −1 PMA, 1 mM ionomycin and Golgi-Plug (1:1,000; BD Biosciences) for 3 h at 37 °C. Surface antigens were stained first, followed by fixation and permeabilization using the Cytofix/Cytoperm kit (BD Biosciences) and staining of intracellular proteins. All antibodies used are listed in Supplementary ;Pik3ca E545K (WEP) tumour material was collected in ice-cold PBS and mechanically chopped using a McIlwain tissue chopper (Mickle Laboratory Engineering). Tumours were subsequently digested for 30 min at 37 °C in 3 mg ml −1 collagenase A, 0.1% trypsin and fungizone in DMEM with 2% FCS. Enzyme reactions were stopped by addition of DMEM and 2% FCS and suspensions were dispersed through a 40-µm cell strainer. Cells were initially cultured in DMEM containing 10% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin, insulin, EGF and cholera toxin. After establishment, mouse cell lines were cultured in DMEM medium supplemented with 8% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin and 2 mM l-glutamine. To ensure relatedness to parental GEMM tumours, polyclonal cells were used at low passage number for all experiments. MCF-7 cells (provided by T.N.S.) were cultured in DMEM medium supplemented with 8% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin and 2 mM l-glutamine. All cell lines were routinely tested for mycoplasma contamination and only mycoplasma-negative cells were used. For in vitro culture of BMDMs, bone marrow was aseptically collected by flushing tibia and femurs from euthanized wild-type mice with sterile RPMI and 8% FCS. Bone marrow cells were cultured for 7 days in RPMI medium supplemented with 8% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin and 10 ng ml −1 recombinant M-CSF (Peprotech). BMDMs were collected at day 7 and examined for CD11b and F4/80 expression by flow cytometry. Consistent purities of >95% CD11b + cells were cultured in RPMI medium supplemented with 8% FCS, 100 IU ml −1 penicillin, 100 mg ml −1 streptomycin and 10 ng ml −1 recombinant M-CSF (Peprotech). MDMs were collected at day 7 and examined for CD11b, CD14 and CD68 expression by flow cytometry. Consistent purities of >95% CD11b
+ cells were obtained. Where indicated, BMDMs and MDMs were exposed to conditioned medium from tumour cell lines, in the presence or absence of LGK974 (1 µM, Selleck Chemicals) for 24 h and harvested for RNA and/or protein isolation. Conditioned medium was obtained by culturing tumour cells at equal confluency in empty DMEM overnight. Cell growth kinetics in vitro were analysed using the IncuCyte System (Essen BioScience). RNA isolation and qRT-PCR. RNA was isolated using either TRIzol or a Qiagen RNeasy column followed by treatment with DNase I (Invitrogen). RNA quality was confirmed with a 2100 Bioanalyzer from Agilent. RNA was converted to cDNA with an AMV reverse transcriptase using Oligo(dT) primers (Invitrogen). cDNA (20 ng per well) was analysed by SYBR green real-time PCR with 500 nM primers using a LightCycler 480 thermocycler (Roche). Actb and/or Gapdh were used as reference genes. Primer sequences used for each gene are listed in Supplementary  Table 2 . Fold change in expression was calculated using 2 -(ΔCt.x − average(ΔCt.control))
. Protein isolation and western blotting. Protein lysates of cells and tissue were prepared using RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS, 2 mM EDTA) complemented with protease and phosphatase inhibitors (Roche) and protein concentration was quantified using the BCA protein assay kit (Pierce). Protein lysate was loaded onto NuPAGE 4-12% Bis-Tris gradient gels (Invitrogen) and transferred onto Trans-Blot Turbo Mini or Midi Nitrocellulose membranes (BioRad) using Trans-Blot Turbo Transfer System (BioRad). Membranes were blocked in 10% Western Blot Blocking Reagent (Roche) or 3% BSA for 1 h at room temperature. Primary antibody incubation was performed overnight at 4 °C. Membranes were washed using TBS and Tween 20 (TBS-T) and subjected to secondary fluorochrome-conjugated antibodies for 1 h at room temperature and protein was detected using the Odyssey CLx imaging system and processed using ImageJ software 1.48v. Antibodies are listed in Supplementary Table 1 . Immunohistochemistry. Immunohistochemical analyses were performed by the Animal Pathology facility at the Netherlands Cancer Institute. Formalin-fixed tissues were processed, sectioned and stained as described 36 . In brief, tissues were fixed for 24 h in 10% neutral buffered formalin, embedded in paraffin, sectioned at 4 µm and stained with haematoxylin and eosin (H&E) for histopathological evaluation. H&E slides were digitally processed using the Aperio ScanScope (Aperio). For immunohistochemical analysis, 5-µm paraffin sections were cut, deparaffinized and stained. Antibodies and antigen retrieval methods are listed in Supplementary  Table 1 . Quantitative analysis of cell abundance was performed by counting cells in five high-power (×40) fields of view (FOV) per tissue by two independent researchers. Samples were visualized with a BX43 upright microscope (Olympus) and images were acquired in bright field using cellSens Entry software (Olympus). To score pulmonary metastasis, single lung sections were stained for cytokeratin-8 and metastatic nodules were counted by two independent researchers. Stained tissue slides were digitally processed using the Aperio ScanScope. Brightness and contrast for representative images were adjusted equally among groups. Cytokine analyses. Quantification of cytokine and chemokine levels in serum was performed using BD Cytometric Bead Array for CCL2, IL-1β, IL-17A and G-CSF according to manufacturer's instructions and analysed on a Beckman Coulter CyAn ADP flow cytometer with Summit software. Data analyses were performed using FlowJo Software version 9.9. CRISPR-Cas9-mediated gene disruption. For knockout of mouse Trp53, p53-proficient tumour cell lines were transfected with lentiCRISPR v2 (provided by F. Zhang (Addgene plasmid 52961) 37 ) containing sgRNA targeting exon 4 (sgRNA1: 5′-TCCGAGTGTCAGGAGCTCCT-3′ and sgRNA2: 5′-AGTGAAGCCCTCCGAGTGTC-3′). For knockout of human TP53, MCF-7 tumour cell lines were transfected with lentiCRISPRv2 containing sgRNA targeting either exon 4 (sgRNA1: 5′-CCATTGTTCAATATCGTCCG-3′) or exon 2 (sgRNA2: 5′-TCGACGCTAGGATCTGACTG-3′). Cloning of sgRNAs in lentiCRISPR was performed as described 37 and sgRNA sequences were designed using the online CRISPR Design tool (http://crispr.mit.edu), of which the two highest scoring sequences were chosen. All vectors were validated by Sanger sequencing. After selection of transfected cells, polyclonal cell lines were used for all subsequent experiments. To determine knockout efficiency, genomic DNA from cell lines was isolated using Viagen DirectPCR Lysis reagent (Cell) supplemented with 200 µg ml −1 proteinase K after transfection and puromycin selection. The mouse Trp53 target region was amplified using PCR with the following primers: forward 5′-GGGGACTGCAGGGTCTCAGA-3′ and reverse 5′-CCACGTCCCCTGGAGAGATG-3′. The human TP53 target region was amplified using PCR with the following primers: FW1 5′-CAGACTG CCTTCCGGGTCAC-3′ for sgRNA1, FW2 5′-TGGGAAGGTTGGAAGT CCCTC-3′ for sgRNA2, and RV 5′-CACTGACAGGAAGCCAAAGGG-3′. PCR products were run on 1% agarose gel, purified using the Illustra GFX PCR DNA and Gel Band Purification Kit (Sigma), and subjected to Sanger sequencing using their respective forward primers. Genome editing efficiency was quantified using the Tracking of Indels by Decomposition (TIDE) algorithm as described (http:// tide.nki.nl) 38 . shRNA-and siRNA-mediated knockdown of genes. Vectors for shRNAs were collected from the TRC library. To allow stable expression of shRNAs, HEK293T cells (provided by T.N.S.) were transfected with the pLKO.1 lentiviral vector encoding shRNAs, pPAX packaging vector and VSV-G envelope vector. Five independent shRNA clones were used for each experiment. Virus was collected at day 4 and 5 and viral titres were determined using the Abm qPCR lentivirus titration kit (LV900). Cell lines were subsequently transduced and selected using puromycin. Knockdown efficiency was determined by RT-qPCR compared to non-targeting controls. The shRNA clone used for Porcn knockdown in all experiments after assessment of knockdown efficiency contained following hairpin sequence: 5′-CAACTTTCTATGCCTGTCAAT-3′ (shPorcn-1) or 5′-CCCATGTCTTATTGGTTAAAT-3′ (shPorcn-4). For in vivo experiments, shPorcn-4 was used. To silence Fzd receptors, BMDMs were transfected with the following siRNA pools (control siRNA (sc-37007), Fzd7 (sc-39991) and Fzd9 (sc-39995), Santa Cruz Biotechnology), according to the manufacturer's instructions. In brief, BMDMs were differentiated as described above, and 24 h before exposure to tumour conditioned medium and BMDMs were suspended in transfection medium and incubated with indicated siRNA pools. After 6 h at 37 °C, 2× RPMI medium was added (RPMI, 20% serum, 200 IU ml −1 penicillin, 200 mg ml
streptomycin and 20 ng ml −1 recombinant M-CSF) and BMDMs were further cultured overnight. After 24 h, the medium was replaced by tumour conditioned medium for 24 h, after which gene expression was assessed. ChIP-seq analysis. ChiP-seq analysis was performed as previously described 39 . tumours (3 cell lines from 3 independent mouse tumours per genotype) were fixed in 1% formaldehyde, crosslinked and processed for sonication. Subsequently, 5 µg of p53 antibody (Supplementary Table 1 ) and 50 µl of protein G magnetic beads (Invitrogen) were used for each ChIP. Eluted DNA was sequenced using the Illumina Hiseq 2500 analyser (using 65 bp reads) and aligned to the Mus musculus mm10 reference genome. Peak calling over input control was performed using and MACS 2.0 peak caller. Data were visualized using Easeq 40 . Overexpression of miR-34a. The MSCV-miR-34a retroviral vector (provided by L. He (Addgene plasmid 63932) 41 ) was transfected in HEK293T cells, together with pGag-Pol and VSV-G vectors to generate retrovirus. Mouse cancer cell lines were exposed to viral supernatant and assessed for expression of WNT target genes after puromycin selection. RNA sequencing and analysis. Total RNA was extracted from tumours using TRIzol reagent (Ambion Life Technologies) according to the manufacturer's instructions. Samples were equimolar pooled and were single-end sequenced for 51 or 65 base pairs on the Illumina Hiseq2000/Hiseq2500 Machine. The reads were aligned against the mouse transcriptome (mm10) using Tophat2 (Tophat version 2.1.0, Bowtie version 1.0.0) that allows for exon-exon junctions 42, 43 . Tophat was guided using a reference genome as well as a reference transcriptome. The reference transcriptome was created using a gene transfer file (GTF) that was downloaded from Ensembl (v.77). Gene counts were generated using a custom script that functions identically to HTSeq-count 44 . Only reads that mapped uniquely to the transcriptome were used for gene expression quantification. Although some of the libraries were generated with strand-specific protocols, all samples have been aligned without taking strandedness into account. Next, differential expression analysis was performed using the R package edgeR 45 in combination with the voom 46 method, using raw read counts as input. Library size normalization was performed during differential expression analysis within the voom function. Genes with P < 0.05 were labelled as differentially expressed. Genes were further filtered for display by requiring them to be protein coding and to have an absolute log 2 -transformed fold change ≥ 3 and a P ≤ 0.01. The selected genes were shown in a heat map of read counts that were normalized to 10 million reads per sample.
For Hallmark pathway analysis of mouse transcriptomes, raw read counts were normalized by trimmed means of M-values computed using the function calcNormFactors (edgeR v.3.20 . 5 45 ), from which counts per million (CPM)-normalized gene expression values were computed for plotting purposes using the same R package. CPM values were subsequently transformed as f(x) = log 2 (x + 1). Ensembl77 mouse gene identifiers were then converted to homologous human gene identifiers using the biomaRt R package (server oct2016.archive.ensembl. org). Gene expression heat maps for hallmark human gene sets obtained from MsigDB 47 were generated using the 'aheatmap' function provided by the NMF R package (version 0.20.6). Heat map columns (containing samples) were ordered according to average linkage (UPGMA) hierarchical sample clustering based on Pearson correlation distances between the expression values of displayed genes. Heat map rows (containing genes) were ordered according to gene expression fold difference between Trp53 −/− and Trp53 +/+ samples. The R language for statistical computing was used (v.3.4.2) for gene expression normalization and heat map generation. Pathway enrichment analysis of Trp53 −/− and Trp53 +/+ tumours was performed using Ingenuity Pathway Analysis software (QIAGEN), analysing differentially expressed genes with P ≤ 0.05. TCGA analysis. To obtain a comprehensive view on the cellular processes affected by p53 deficiency in human breast cancer, we performed a gene set enrichment analysis (GSEA) using a 50 hallmark gene sets (Liberzon) 47 on the TCGA breast cancer (BRCA) cohort. First, we classified p53 deficiency based on mutational status. DNA sequencing variant calls (MAF-file) for the BRCA cohort were downloaded from the 21 August 2015 release of the Broad TCGA genome data analysis centre standard run (http://gdac.broadinstitute.org/runs/stddata). We used two classifications for p53 deficiency: in the first classification (labelled 'any TP53 mutation'), patients with any kind of TP53 mutation were classified as p53 deficient. In the second classification (labelled 'IARC TP53 database'), only patients with a dominant-negative TP53 mutation as annotated using the IARC TP53 mutation database 48 (release 18, matched on protein effect of the mutation) were labelled as p53 deficient, as well as patients with gain-of-stop, stop-lost or frameshifting mutations (n = 161). One sample had a trans-activating mutation and was excluded from the analysis. The remaining samples were labelled as p53 proficient (n = 793).
Next, TCGA RNA sequencing data were downloaded from the Broad TCGA genome data analysis centre 1 November 2015 release of the standard runs. We ran a GSEA on the 50 Hallmark gene set using the flexgsea-r R package (https://github. com/NKI-CCB/flexgsea-r) on the read counts normalized with limma voom with the span parameter set to 0.5 46 . Within each permutation of the sample labels, genes were ranked for association with p53 proficiency using the moderated t-statistic from the limma empirical Bayes function (ebayes() ran on the result of lmFit()). Reported FDR-values were obtained from the flexgsea-r output.
Single gene associations with TP53 status in human breast tumours of the TCGA BRCA cohort and correlation coefficients between WNT-related genes and TP53 status (mutant versus wild type) were analysed using R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl/) and visualized using GraphPad Prism version 7. Statistics and reproducibility. Data analyses were performed using GraphPad Prism (version 7). The statistical tests used are described in figure legends. All tests were performed two-tailed. P < 0.05 was considered statistically significant. All western blot and RT-qPCR analyses were independently repeated more than twice. Sample sizes were based on previous experiments 5, 17, 36 or determined using G*Power software (version 3.1). To exclude bias towards one particular GEMM in the analyses for Fig. 1 , we have performed the same analyses on the average of the neutrophil levels and serum cytokine values per model. This demonstrated the same correlations between the assessed values and p53 status of the tumour, thus excluding bias towards one or several particular models. Principal component analysis was performed using the prcomp-function in R (version 3.4.2), both centering and scaling the input data before applying dimensionality reduction. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
The RNA-sequencing data have been deposited in the Gene Expression Omnibus (GEO, NCBI) repository under accession number GSE112665. All other data are found in the Source Data, Supplementary Information or available from the authors on reasonable request. cKIT expression on gated total neutrophils in blood is shown (gating was based on blood of wild-type mice). Quantification and statistical analysis of these data are found in Fig. 1a , b.
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Extended Data Fig. 2 | CRISPR-Cas9-mediated +/+ (n = 5) and WEP;Trp53 −/− (n = 5) cell lines, with t = 0 being the first day tumours were palpable. h, Gating strategy to identify circulating neutrophils and their cKIT expression. i, Gating strategy to identify neutrophils in the lung. j, Representative images of spleens from mice bearing WEA;Trp53 +/+ and WEA;Trp53 −/− tumours and quantification of spleen area (length × width) at end stage (tumour volume 1,500 mm 3 ) of mice bearing p53-proficient (n = 4) and p53-deficient WEA (n = 6) and WEP (n = 5 per group) tumours. All data are mean ± s.e.m. P values were determined by area under the curve (AUC) analysis followed by two-tailed Welch's t-test (c, d, f, g ) or two-tailed Mann-Whitney U-test (j). ns, not significant. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection Flow cytometry data: data acquisition was performed on BD LSRII flow cytometer using Diva software (BD Biosciences) or Beckman Coulter CyAn ADP flow cytometer with Summit software. For RNAseq of murine tumours: sequenced using on the Illumina Hiseq2000/Hiseq2500 Machine For IHC: for individual images, cellSens Entry software (Olympus). For digital processing, slides were scanned using the Aperio ScanScope (Aperio, Vista, CA). Cell growth kinetics in vitro were analysed using the IncuCyte System (Essen BioScience). For RT-qPCR: LightCycler 480 thermocycler (Roche). For western blot: Odyssey CLx imaging system Data analysis Statistical analyses were performed using GraphPad Prism 7/8 (GraphPad Software Inc., La Jolla, CA). Flow cytometry data analysis was performed using FlowJo software version 9.9. For images: ImageJ software 1.48v For the mouse RNA-Seq/human TCGA analysis: R software version 3.4.2, Tophat2 (Tophat version 2.1.0 / Bowtie version 1.0.0), edgeR R package version 3.20.5, biomaRt R package, NMF R-package version 0.20.6, Ingenuity Pathway analysis version 01-06 (QIAGEN), flexgsear R package and R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl/) were used. Principal component analysis was performed using the prcomp-function in R (version 3.4.2) For ChIP-sequencing: Easeq software was used for visualisation. For power calculations and group size determination: G*Power software (version 3.1).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The RNA sequencing datasets have been deposited in the Gene Expression Omnibus (GEO, NCBI) repository under accession number GSE112665.
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Sample size
Sample size was based on previous experience with the mouse models (Coffelt et al., 2015; Doornebal et al., 2013) or otherwise determined using G*Power software version 3.1. For immunohistochemistry, flow cytometry and RT-qPCR experiments, ≥3 biological replicates were used. For the intervention experiment assessing metastasis, ≥ 9 mice were used. To exclude bias towards one particular GEMM in the analyses for Figure 1 , we have performed the same analyses on the average of the neutrophil levels and serum cytokine values per model. This demonstrated the same correlations between the assessed values and p53 status of the tumour, thus excluding bias towards one or several particular models.
Data exclusions Mice with skin tumours (in the models in which Keratin-14 (K14) drives expression of Cre recombinase, skin tumours can arise, since K14 is also expressed in the skin) were excluded from the study, based on assessment of H&E stainings of the tumour. For orthotopic transplantation of cancer cell lines, samples were excluded when not properly transplanted in the mammary fat pad (e.g. in the skin adjacent to the mammary gland). For metastasis scoring in the KEP-tumour based metastasis model, mice that died because of reasons not related to metastasis were excluded (surgery-related or local recurrance of the primary tumour after surgery). In the WEP cell line-based metastasis model, samples were excluded when smaller tumours, due to their invasive behaviour, grew through the skin before the end of the experiment (1200 -1500 mm3 tumour size), to allow all tumours sufficient time to metastasize. For RT-PCR analysis, samples were run in technical duplicate and if the difference between the Ct values of the duplo was bigger than 1 cycle, samples were discarded. Exclusion criteria were pre-determined before the experiments.
Replication
In vitro experiments were repeated in at least 2 -3 independent experiments and showed comparable results between experiments.
Randomization For intervention studies, mice were randomly distributed over the two treatment arms when tumours reached the size indicated in the figures. The first animal was assigned randomly in the treatment or control group, after which each subsequent animal was placed in the next group.
Blinding
Tumour measurements and post mortem analyses were performed in a blinded fashion. Assessment of IHC counts were performed by 2 or more independent researchers in a blinded fashion.
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